Pediatrics Doctors in Strongsville, OH Accepting Medicare

6 Pediatrics doctors found. Showing 1 - 6

Heidi A Senokozlieff, DO Pediatrics Medicare: Medicare Enrolled Practice Location: 16761 Southpark Ctr, Strongsville, OH 44136 Phone: 440-878-2500    Fax: 440-878-3185

Gregory Golonka, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 18181 Pearl Rd Ste A200, Strongsville, OH 44136 Phone: 440-816-4950    Fax: 440-819-4960

Kylie Holway Liermann, D.O. Pediatrics Medicare: Medicare Enrolled Practice Location: 16761 Southpark Ctr, Strongsville, OH 44136 Phone: 440-878-2500

Christopher P Rizzo, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 12516 Saddlebrook Ln, Strongsville, OH 44149 Phone: 330-592-5884    Fax: 301-398-7823

Dr. James Michael Wertman, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 17406 Royalton Rd, Strongsville, OH 44136 Phone: 216-524-7377    Fax: 440-846-2832

Dr. Walter R Lucas, M.D. Pediatrics - Adolescent Medicine Medicare: Not Enrolled in Medicare Practice Location: 17075 Pearl Road, Strongsville, OH 44136 Phone: 440-572-0422

News Archive

Raptor Pharmaceutical acquires exclusive license to intellectual property for Huntington's Disease treatment

Raptor Pharmaceutical Corp., announced that the Company has acquired an exclusive worldwide license to intellectual property related to the potential treatment of Huntington's Disease from the Weizmann Institute of Science in Israel and Niigata University in Japan. In addition, Raptor has added Professor Lawrence Steinman, M.D., an inventor on the Weizmann patent, to its Advisory Board.

Abnormal glutamine repeats interfere with key transcription factor, leading to neurodegeneration

Although repeating sequences of three nucleotides encoding some of the bodies' 20 amino acids are a normal part of protein composition, abnormal expansion of trinucleotide repeats is the known cause of multiple inherited neurodegenerative disorders, including Huntington disease.

GSK and University of Leicester team up to develop novel drugs to treat blood cancer

A collaboration between the University of Leicester and global pharmaceutical company GlaxoSmithKline has been established to discover and develop novel medicines to treat aggressive forms of blood cancer.

New study may help develop targeted therapies for controlling tissue destruction

Stroke, heart attacks and numerous other common disorders result in a massive destruction of cells and tissues called necrosis. It's a violent event: As each cell dies, its membrane ruptures, releasing substances that trigger inflammation, which in turn can cause more cellular necrosis.

Read more Medical News

› Verified 5 days ago